Brain 17 Vienna

Low grade astrocytoma

• Chemotherapy can be a therapeutic option to defer, or an alternative to RT at progression, but, deferring RT must be balanced with the lower control of seizures and shorter PFS 1,2 • Long term results of athe RTOG 9802 trial showed a survival advantage of 5.5 years by addition of chemotherapy to RT in patients with adverse prognostic factors 2 • The same experience indicates that treatment of LGG patients, immediately after surgery or at progression, should be tailored according to specific prognostic factors 1-5 • Patients’ subgroups should be treated and trials should be designed according to specific biomarkers, being IDH mutation and 1p/19q codeletion the most relevant 1-5

1. 2. 3. 4. 5.

Baumert, et al. Lancet Oncol 2016 Buckner, et al., NEJM 2016 Soffietti, et al. EJN 2010 Gorlia, et al. Neuro-Oncol 2013 Weller, et al, Lancet Oncol, 2017